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֗ᗷ֏ۨદైΖ
࿨࣠Κڇ 142 ۯఐԳၴΔCAD ֗ʳDR ऱฐ۩෷։ܑ੡ʳ24%֗ʳ18.3%ΖCAD ۿ׏ፖࠟႈڂ՗ڶ
ᣂΚڣ᤿ʳˑ 6ʳ0ᄣʳ (p =ʳ 0.08) ֗೏ۨᚘ୮ග׾ (p =ʳ 0ʳ.058)Δ׊ࣔ᧩ፖψإൄೣ೏ωპၦػ๨ػݟ఑ڶ
Coronary Artery Disease Associated With Low-Grade 
Albuminuria in Type 2 Diabetes Mellitus
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Microalbuminuria can be measured in 24-hour urine samples for early detection of patients at high risk of de-
veloping vascular complications. The present study investigated the relation between vascular disease and 
normal levels of urinary albumin. The prevalence of coronary artery disease (CAD) and diabetic retinopathy 
(DR) was investigated in 145 patients with type 2 diabetes who had normal renal function. The patients were 
classified according to levels of microalbuminuria (normal ≤ 14 mg/24 hr, high-normal > 14 mg/24 hr 
to < 30 mg/24 hr). The association between CAD and DR and various patient parameters were investigated, in-
cluding sex, age, time of diagnosis, family history of diabetes, smoking habits, body mass index, abdominal 
circumference, high blood pressure, absence of nocturnal blood pressure fall as registered by ambulatory 24-hour 
monitoring, retinopathy, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein choles-
terol, triglycerides, and glycosylated hemoglobin. The overall prevalence of CAD was 24.0% and that of DR 
was 18.3% among the 142 patients. A trend was observed toward an association of CAD with age > 60 years 
(p = 0.08) and family history of hypertension (p = 0.058). A significant association was found between CAD and 
high-normal microalbuminuria (relative risk 2.79; 95% confidence interval 1.88–4.16; p < 0.001). DR was sta-
tistically associated with female sex (p = 0.028) and duration of diagnosis > 5 years (p = 0.022). DR displayed 
a tendency for association with an absence of nocturnal blood pressure fall (p = 0.067), but was not statistically 
associated with either of the two levels of microalbuminuria (p = 0.657). CAD is significantly associated 
with the level of microalbuminuria > 14 mg/24 hr. The presence of DR could not be statistically associated with 
high-normal levels of microalbuminuria. [Hong Kong J Nephrol 2011;13(1):27–32]
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Coronary artery disease (CAD) is the main cause of death 
in patients with diabetes mellitus (DM) [1–3]. Diabetic 
retinopathy is frequently associated with microvascu-
lopathy in DM, and is the main cause of blindness among 
adults 20–74 years of age in the United States [4]. An 
association between diabetic retinopathy (DR) and 
mortality has been demonstrated in past studies [5,6].
Clinical and experimental studies have demonstrated 
that the presence of microalbuminuria is a marker for 
diabetic nephropathy and cardiovascular disease [7–11]. 
Microalbuminuria is also an independent risk factor for 
cardiovascular mortality in DM [9,12]. The presence of 
normal levels of albumin in the urine is suggestive of 
being at low risk for developing renal disease, but some 
studies have demonstrated that some of these patients 
have well-established renal lesions [13]. Microalbumin-
uria in 24-hour urine samples may be measured for early 
detection of patients at high risk for developing vascu-
lar complications. It is known that reducing microalbu-
minuria during treatment translates to a reduction in 
cardiovascular events [14].
The traditional upper limit of normal daily albumin 
excretion has been 30 mg/24 hr, but more recent data 
suggest that levels in the general population are actually 
much lower. Within this range of low-grade albuminuria, 
increasing excretion rates are associated with increasing 
risk of cardiovascular disease [15]. Higher levels of 
albumin excretion within the normal range are associ-
ated with cardiovascular disease in high-risk individuals 
[16]. The present study was performed to investigate the 
relation between vascular disease and “normal” levels of 
albuminuria (low-grade albuminuria). For this purpose, 
we evaluated the association between macrovascular 
complications (CAD) and microvascular complications 
(DR) and two levels of albuminuria.
METHODS
This cross-sectional study was conducted on patients 
with diabetes mellitus type 2 who were being followed 
in a specialized center in Fortaleza, Brazil between 
March 2002 and April 2003. A total of 170 patients were 
randomly selected, and an investigation was established 
to determine the prevalence of CAD and DR in regard 
to two levels of microalbuminuria (normal ≤ 14 mg/24 hr, 
high-normal > 14 mg/24 hr but < 30 mg/24 hr). Patients 
were included who met the inclusion criteria: normal 
level of microalbuminuria (< 30 mg/24 hr), assessed dur-
ing the last 12 months on at least two occasions, normal 
renal function (glomerular filtration rate > 90 mL/min), 
and regular use of oral hypoglycemic drugs or insulin. 
Among the 170 patients initially selected, 24 were ex-
cluded after a new laboratory evaluation, because they 
had microalbuminuria > 30 mg/day, and 1 patient had 
a psychiatric disorder. The Ethics Committee of the 
Federal University of Ceará, Brazil approved the study.
Laboratory procedures
The main clinical and laboratory parameters studied were 
defined as follows: smoking (the patient was smoking at 
the time of the medical visit or had a history of smoking), 
obesity [body mass index (BMI) > 30 kg/m2], hypertension 
(blood pressure > 140/90 mmHg assessed by ambulatory 
24-hour monitoring or taking antihypertensive drugs), 
dyslipidemia [total cholesterol > 200 mg/dL, low density 
lipoprotein (LDL) > 100 mg/dL or high density lipopro-
tein (HDL) < 40 mg/dL for men and < 50 mg/dL for 
women, or triglycerides > 150 mg/dL], DR (presence of 
microaneurysms, venous dilation, hemorrhage, and 
exudates characteristic of nonproliferative retinopathy; 
or neovascularization, fibrous proliferation, preretinal 
hemorrhage, and vitreal hemorrhage characteristic of 
proliferative retinopathy), CAD (history of acute myo-
cardial infarction, history of myocardial revasculariza-
tion, angiography positive for coronary disease), normal 
fasting blood glucose (70–110 mg/dL), glycosylated 
hemoglobin (normal < 6.4%), serum creatinine (nor-
mal < 1.2 mg/dL), normal microalbuminuria (urinary 
albumin excretion < 30 mg/24 hr).
Statistical analysis
The association between independent variables and 
outcomes (CAD and DR) was analyzed by the χ2 test 
or Fisher’s exact test when appropriate. A multivariate 
analysis was performed. Results were expressed as the 
mean ± standard deviation in the cases of quantitative 
variables. The descriptive values below 5% (p < 0.05) 
were considered statistically significant. Statistical 
analysis was performed with Stata 10 software (Data 
Analysis Statistical Software; StataCorp LP, College 
Station, TX, USA).
ᣂʳ(RR =ʳ 2ʳ.79; 95% CI, 1.88–4.16; p < 0ʳ.001)ΖDRʳঞࣔ᧩ፖՖࢤࢤܑ (p =ʳ 0ʳ.028) ်֗ឰழၴʳˑ 5ʳ ڣڶ
ᣂ (p =ʳ 0ʳ.022)Δٍױ౨ፖ࡙ၴۨᚘآנ෼Հ૾ڶᣂ (p =ʳ 0ʳ.067)Δ܀ፖპၦػ๨ػݟ఑ֽؓऱᣂএঞ
آሒอૠᖂრᆠʳ(p =ʳ 0ʳ.657)Ζ
࿨ᓵΚCAD ऱژڇፖპၦػ๨ػݟ఑ʳˑ 1ʳ4 mg/24 hr ࣔ᧩ڶᣂΙ܀ʳDRʳऱژڇፖპၦػ๨ػݟ఑հ
ၴऱᣂএঞآሒอૠᖂრᆠΖ
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RESULTS
A total of 145 diabetic patients were included. All pa-
tients had normal microalbuminuria, as expected. The 
clinical and laboratory parameters are summarized in 
Table 1. Among these patients, 53% were > 60 years and 
57% were female.
The prevalence of CAD was 24.1%. DR was found in 
18.3% of cases, 14.5% being nonproliferative. Hyper-
tension was seen in 69% of patients, of whom 93% were 
taking antihypertensive drugs (including an angiotensin-
converting enzyme inhibitor).
The mean fasting blood glucose was 193.1 ± 79.4 
mg/dL, and the mean glycosylated hemoglobin was 
7.8 ± 1.9%. The mean 24-hour urinary albumin level was 
11.9 ± 7.0 mg, with 51 (35.2%) patients presenting with 
albuminuria > 14 mg. The mean total cholesterol level 
was 208.7 ± 44.1 mg/dL, and 54.5% of patients had a 
level > 200 mg/dL.
The mean BMI was 27.5 ± 4.7 kg/m2. Obesity was found 
in 24.1% of patients. The mean abdominal circumference 
was 99.4 ± 11.3 cm in men and 98.9 ± 11.4 cm in women.
The prevalence of CAD and DR according to the 
two levels of albuminuria are shown in Table 2. In the 
group with higher levels of albuminuria the prevalence 
of CAD was 47.1% (higher than in the group with lower 
levels, p < 0.001). The prevalence of DR was similar in 
the two groups (p = 0.65).
The prevalence of other risk factors for cardiovas-
cular disease among patients with microalbuminuria 
> 14 mg/24 hr and ≤ 14 mg/24 hr is summarized in Table 3. 
There was a tendency for an association between CAD 
and age > 60 years (p = 0.086). There was no significant 
association between CAD and total cholesterol, HDL, 
LDL, triglycerides, or glycosylated hemoglobin.
There was a significant association of DR with the 
patient’s sex (p = 0.028) and duration of diagnosis > 5 
years (p = 0.022). There was no association of DR with 
total cholesterol, HDL, LDL, triglycerides, or glycosyl-
ated hemoglobin.
There was no association between microalbuminuria 
and sex, age, time of diagnosis, family history of dia-
betes, smoking, BMI, obesity, and DR. There was also 
no association between microalbuminuria and total 
cholesterol, HDL, LDL, triglycerides, or glycosylated 
hemoglobin.
DISCUSSION
An investigation regarding an association between CAD 
and DR with two levels of microalbuminuria (both 
considered normal) was conducted. CAD was found in 
an important percentage of patients (24%). The preva-
lence of CAD among diabetic patients varies between 
25% and 50%, depending on the diagnostic criteria [17].
Microalbuminuria was initially recognized as a 
predictor of renal disease [18,19], and it was then con-
sidered as a risk factor for cardiovascular disease, being 
associated with other traditional risk factors, such as 
age, hypertension, smoking, left ventricular hypertro-
phy, obesity, and hyperglycemia [20]. There is evidence 
Table 1. Clinical and laboratory parameters of 145 patients with type 
2 diabetes with normal urinary microalbumin testsa
Parameter Mean ± SD or %
Age (yr) 60.8 ± 11.5
Sex (%)
 Male 42.1
 Female  57.9
Duration of diabetes (yr) 8.1 ± 6.5
Body mass index (kg/m2) 27.5 ± 4.7
Coronary artery disease (%) 24.1
Hypertension (%) 69.0
Diabetic retinopathy (%) 18.3
Family history of diabetes (%) 69.7
Family history of hypertension (%) 80.7
Abdominal circumference (cm)
 Men 99.4 ± 11.3
 Women 98.9 ± 11.4
Smoking (%) 10.3
Creatinine (mg/dL) 0.9 ± 0.2
Total cholesterol (mg/dL) 208.7 ± 44.1
HDL (mg/dL) 42.6 ± 11.2
LDL (mg/dL) 127.6 ± 35.9
Triglycerides (mg/dL) 208.7 ± 199.3
Fasting blood glucose (mg/dL) 193.1 ± 79.4
Glycosylated hemoglobin (%) 7.8 ± 1.9
Microalbuminuria (mg/24 hr) 11.9 ± 7.0
Use of antihypertensive drugs (%) 64.1
Use of oral hypoglycemic drugs (%) 85.5
Use of insulin (%) 32.4
aContinuous data are expressed as mean ± standard deviation 
and nominal data are expressed as a percentage.
Table 2. Prevalence of coronary artery disease among 145 patients 
with type 2 diabetes according to microalbuminuria test results
 Microalbuminuria Microalbuminuria
 ≤ 14 mg/24 hr > 14 mg/24 hrPathology
 n (%) n (%) 
p
CAD 11 (11.7) 24 (47.1) < 0.001
Diabetic 18 (19.4)  8 (16.3)  0.657
 retinopathy
Significance is at p < 0.05. CAD = coronary artery disease.
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that renal dysfunction is a common and powerful car-
diovascular risk factor, and that treatment strategies 
intervening in the renin-angiotensin-aldosterone system 
can be used to target microalbuminuria and reduce 
cardiovascular and renal risk [21]. In a study that in-
cluded 2,600 patients with cardiovascular disease, the 
combination of a decreased glomerular filtration rate 
with albuminuria was associated with vascular events, 
vascular mortality, and overall mortality [22]. Another 
study showed that macroalbuminuria is associated with 
a high risk of congestive heart failure (odds ratio, 4.3; 
95% confidence interval, 1.5–11.7) [23]. Jassal et al [24] 
in a study comparing the risk of cardiovascular disease 
between men and women found a twofold higher risk 
among women with microalbuminuria and metabolic 
syndrome. Around 70% of the population have increased 
albumin urinary excretion, and consequently increased 
cardiovascular risk [25]. Renal disease associated with 
hypertension and microalbuminuria is also associated 
with a high mortality rate [26].
Our findings show that the prevalence of CAD was 
higher among patients with high-normal levels of mi-
croalbuminuria (> 14 mg/24 hr). Gerstein et al [27] 
studied 9,034 diabetic and nondiabetic patients > 55 
years of age and concluded that microalbuminuria lower 
than the normal cutoff is associated with increased risk 
for cardiovascular disease. MacLeod et al [28], in a study 
with 153 diabetic patients, compared three groups of 
albuminuria—microalbuminuria (30.0–149.9 μg/min), 
“on the edge” albuminuria (10.6–29.9 μg/min), normal 
albuminuria (< 10.69 μg/min)—and concluded that pa-
tients with high-normal levels of microalbuminuria had 
more cardiovascular disease. It suggested that cardio-
vascular risk is increased even before the development 
of microalbuminuria (> 30 μg/min). Kramer et al [29], in 
a population-based study with 6,814 individuals, found 
that geometric mean coronary artery calcification scores 
were higher among participants with high-normal uri-
nary albumin excretion (8.8; p = 0.07), microalbuminuria 
(9.9; p = 0.002), and macroalbuminuria (13.1; p = 0.02) 
compared with normal urinary albumin excretion (7.4), 
but only microalbuminuria reached statistical signifi-
cance. The mean left ventricular mass was significantly 
higher in participants with high-normal albuminuria 
(37.0; p = 0.001), microalbuminuria (38.3; p ≤ 0.0001), 
and macroalbuminuria (42.3; p ≤ 0.0001) compared with 
those with normal albuminuria (36.0). They concluded 
that levels of excreted urinary albumin below the level of 
microalbuminuria may reflect the presence of subclinical 
cardiovascular disease in patients with diabetes.
The lipid profiles for the patients revealed high 
cholesterol levels in more than 50% of the studied cases. 
In patients with type 2 diabetes mellitus, low HDL 
levels and high triglyceride levels are frequent [30], as 
observed in our study as well. Hypertension was found 
in 69% of patients in the present study, which is com-
patible with data in the literature. The prevalence of 
hypertension is around 40–60% in diabetic people aged 
Table 3. Prevalence of risk factors for cardiovascular disease among 145 patients with type 2 diabetes according to microalbuminuria test 
results
 Microalbuminuria Microalbuminuria
 ≤ 14 mg/24 hr (n = 94) > 14 mg/24 hr (n = 51)Risk factor
 n (%) n (%) 
p
Sex
 Male 38 (40.0) 23 (45.0) 0.60
 Female 56 (60.0) 28 (55.0) 
Age > 60 yr 50 (53.0) 27 (53.0) 1.00
Duration of diagnosis > 5 yr 50 (53.0) 28 (54.9) 0.86
Glycosylated hemoglobin > 7.3% 52 (55.3) 30 (58.8) 0.72
Hypertension (mmHg) 63 (67.0) 37 (72.5) 0.57
BMI > 30 (kg/m2)  24 (25.5) 11 (21.5) 0.68
Abdominal circumference (cm) > 102 (men) or 60 (63.8) 31 (60.7) 0.72
 > 88 (women)
Smoking 8 (8.5) 7 (13.7) 0.39
Total cholesterol > 200 mg/dL 53 (56.3) 26 (51.0) 0.60
HDL (mg/dL) < 40 (men) or < 50 (women) 62 (66.0) 27 (53.0) 0.15
LDL > 100 mg/dL 67 (71.2) 36 (70.5) 1.00
Triglycerides > 150 mg/dL 56 (60.0) 23 (45.0) 0.11
Diabetic retinopathy 18 (19.1) 8 (15.6) 0.65
Significance is at p < 0.05. BMI = body mass index; HDL = high density lipoprotein; LDL = low density lipoprotein.
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45–75 years [31]. In the present study, there was no as-
sociation between hypertension and CAD (p = 0.10). 
These data are not in accord with those in the literature, 
which indicate that hypertension is one of the most im-
portant risk factors for cardiovascular disease, and its 
prevalence is almost twofold higher in diabetic patients 
[32]. We believe that this lack of association in our data is 
due to the number of patients enrolled, although there was 
a trend to significance. Other studies have shown that 
the treatment of hypertension decreases coronary events 
[33,34]. One study showed that hyperglycemia is a risk 
factor for the incidence of hypertension in patients with 
type 1 diabetes, and intensive insulin therapy reduces the 
long-term risk of developing hypertension [35].
In the present study, there was also no association 
between DR and CAD (p = 0.592). This is also not ac-
cord with data in the literature, where DR is considered 
a risk factor for cardiovascular disease. The Framingham 
Study found an association between DR and cardiovas-
cular disease in patients aged 65–74 years and a negative 
association in patients aged 75–85 years [36].
There was no association between CAD and the 
parameters used to assess metabolic control (cholesterol, 
glycosylated hemoglobin, hypertension). This fact can 
be attributed to the homogeneous distribution of these 
variables among the studied population. The analysis 
of microalbuminuria at the higher level (high normal) 
found a positive association with CAD.
Diabetic retinopathy was the other outcome studied 
here. It is the clinical expression of microvascular dis-
ease in diabetes, and was found in 18.3% of the studied 
patients. The prevalence of DR in the literature varies 
widely. There was no association between DR and the 
levels of albuminuria in the present study (p = 0.65). 
Torffvit et al [37], in a study with 476 patients with 
diabetes type 1, found no association of DR with various 
levels of albuminuria. Wirta et al [38] in a study of 174 
patients with type 2 diabetes showed that the presence 
of microalbuminuria was associated with DR when 
compared with normoalbuminuria. The absence of a 
significant association between DR and albuminuria 
demonstrates the possibility of kidney abnormalities 
even without retinopathy, demonstrating the importance 
of a macrovascular disorder in the absence of significant 
microvascular disease.
There was also no association between microal-
buminuria and sex, age, duration of diagnosis, family 
history of diabetes, smoking, BMI, obesity, DR, total 
cholesterol, HDL, LDL, triglycerides, or glycosylated 
hemoglobin.
CONCLUSION
Coronary artery disease is significantly associated with 
levels of albuminuria > 14 mg/24 h (which is still normal). 
The presence of DR cannot be statistically associated 
with high-normal levels of albuminuria. The absence of 
association between CAD and the clinical and laboratory 
parameters analyzed here suggests that there is no con-
founding factor for the association between CAD and 
albuminuria. The definition of normal albuminuria 
should be revised, at least with regard to macrovascular 
complications.
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